wEight chanGes, caRdio-mEtabolic risks and morTality in patients with hyperthyroidism (EGRET): a protocol for a CPRD-HES linked cohort study.
INTRODUCTION: Hyperthyroidism is a common condition affecting up to 3% of the UK population. Treatment improves symptoms and reduces the risk of atrial fibrillation and stroke that contribute to increased mortality. The most common symptom is weight loss, which is reversed during treatment. However, the weight regain may be excessive, contributing to increased risk of obesity. Current treatment options include antithyroid drugs, radioiodine and thyroidectomy. Whether there are differences in either weight change or the long-term cardiometabolic risk between the three treatments is unclear.
METHODS AND ANALYSIS: The study will establish the natural history of weight change in hyperthyroidism, investigate the risk of obesity and risks of cardiometabolic conditions and death relative to the treatment. The data on patients diagnosed with hyperthyroidism between 1 January 1996 and 31 December 2015 will come from Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office of National Statistics Death Registry. The weight changes will be modelled using a flexible joint modelling, accounting for mortality. Obesity prevalence in the general population will be sourced from Health Survey for England and compared with the post-treatment prevalence of obesity in patients with hyperthyroidism. The incidence and time-to-event of major adverse cardiovascular events, other cardiometabolic outcomes and mortality will be compared between the treatments using the inverse propensity weighting model. Incidence rate ratios of outcomes will be modelled with Poisson regression. Time to event will be analysed using Cox proportional hazards model. A competing risks approach will be adopted to estimate comparative incidences to allow for the impact of mortality.
ETHICS AND DISSEMINATION: The study will bring new knowledge on the risk of developing obesity, cardiometabolic morbidity and mortality following treatment for hyperthyroidism to inform clinical practice and public health policies. The results will be disseminated via open-access peer-reviewed publications and directly to the patients and public groups (Independent Scientific Advisory Committee protocol approval #20_000185).
|投稿者||Torlinska, Barbara; Hazlehurst, Jonathan M; Nirantharakumar, Krishnarajah; Thomas, G Neil; Priestley, Julia R; Finnikin, Samuel J; Saunders, Philip; Abrams, Keith R; Boelaert, Kristien|
|組織名||Institute of Applied Health Research, University of Birmingham, Birmingham, UK;email@example.com.;NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS;Foundation Trust, Birmingham, UK.;Institute of Applied Health Research, University of Birmingham, Birmingham, UK.;Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS;Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners.;University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.;Midlands Health Data Research UK, University of Birmingham, Birmingham, UK.;British Thyroid Foundation, Harrogate, UK.;Ridgacre Medical Centres, Birmingham, UK.;Department of Statistics, University of Warwick, Coventry, UK.;Centre for Health Economics, University of York, York, UK.|